Tower Research Capital (TRC)’s TriSalus Life Sciences TLSI Stock Holding History

Tower Research Capital (TRC)’s Portfolio TLSI Stock Details TLSI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2K	Sell	3,118 -8,285	-73%	-$32.9K	﹤0.01%	3822
2026 Q1	$45.6K	Buy	11,403 +9,630	+543%	+$47.2K	﹤0.01%	2820
2025 Q4	$12.4K	Sell	1,773 -1,240	-41%	-$6.94K	﹤0.01%	3487
2025 Q3	$14K	Buy	3,013 +2,915	+2,974%	+$13.6K	﹤0.01%	3633
2025 Q2	$534	Buy	+98	New	+$526	﹤0.01%	5001
2025 Q1	–	Sell	-555	Closed	-$2.78K	–	5784
2024 Q4	$2.78K	Sell	555 -1,148	-67%	-$4.85K	﹤0.01%	4775
2024 Q3	$7.85K	Sell	1,703 -4,217	-71%	-$22.3K	﹤0.01%	4011
2024 Q2	$32.7K	Buy	5,920 +4,378	+284%	+$37.1K	﹤0.01%	3420
2024 Q1	$15K	Sell	1,542 -431	-22%	-$3.98K	﹤0.01%	3263
2023 Q4	$16.7K	Buy	+1,973	New	+$10.2K	﹤0.01%	3772
2022 Q1	–	Sell	-1,336	Closed	-$13K	–	6554
2021 Q4	$13K	Buy	1,336 +643	+93%	+$6.39K	﹤0.01%	4205
2021 Q3	$7K	Buy	+693	New	+$6.78K	﹤0.01%	4674
2021 Q2	–	Sell	-100	Closed	-$1K	–	5841
2021 Q1	$1K	Buy	+100	New	+$1.01K	﹤0.01%	5219

Other funds holding TLSI

FLAM

First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Cerity Partners New York $82.7B AUM 28.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

GGHC

Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

WPC

White Pine Capital Bloomington, Minnesota $423M AUM 67.01% 1-Year Est. Return

TSW

Thompson Siegel & Walmsley Richmond, Virginia $5.57B AUM 9.46% 1-Year Est. Return

Tower Research Capital (TRC)'s TLSI Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its TriSalus Life Sciences (TLSI) stake by 73% in Q2 2026, selling an estimated $32.9K and leaving 3,118 shares worth $14.2K. The position accounts for ﹤0.01% of the portfolio, ranked #3822.

Tower Research Capital (TRC) first reported a position in TLSI in Q1 2021 and has held it in 13 quarters since. The position peaked at $45.6K in Q1 2026. 79 funds tracked by Wall St. Rank hold TLSI as of Q2 2026.

Tower Research Capital (TRC) held 3,118 shares of TriSalus Life Sciences worth $14.2K as of Q2 2026.
Tower Research Capital (TRC) sold 8,285 TriSalus Life Sciences shares in Q2 2026, an estimated $32.9K.
TriSalus Life Sciences made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3822 holding.
Tower Research Capital (TRC) first reported a position in TriSalus Life Sciences in Q1 2021 and has held it in 13 quarters since.
Tower Research Capital (TRC)'s TriSalus Life Sciences position peaked at $45.6K in Q1 2026.
79 funds tracked by Wall St. Rank held TriSalus Life Sciences as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.